Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDU-VAC: Reduced Dose Comirnaty Booster in Healthy Adults
2021-002088-23Phase 4Completed
- Sponsor
- Sciensano
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Sciensano. Primary endpoint: Anti-RBD binding antibody level at day 28 after third dose. Started Apr 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002088-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002088-23.